Agents to treat BRAF-mutant lung cancer

Article Page

Abstract

BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy, but responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another effective tool to attain better response rates when compared to cytotoxic chemotherapy. New strategies such as immunotherapy are becoming as well another option to treat in the second-line setting patients with BRAF-mutated NSCLC.

Keywords: dabrafenib, immunotherapy, lung neoplasm, protooncogene protein B-raf, trametinib.

Citation: Bustamante Alvarez JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs in Context 2019; 8: 212566. DOI: 10.7573/dic.212566

Contributions: Both authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2019/01/dic.212566-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2019 Bustamante Alvarez JG, Otterson GA. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Bustamante Alvarez JG, Otterson GA. https://doi.org/10.7573/dic.212566. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://drugsincontext.com/agents-to-treat-braf-mutant-lung-cancer

Correspondence: Gregory A Otterson, Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, B450 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210. Greg.Otterson@osumc.edu

Provenance: invited; externally peer reviewed.

Submitted: 18 October 2018; Peer review comments to author: 6 December 2018; Revised manuscript received: 28 January 2019; Accepted: 29 January 2019; Publication date: 13 March 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF